Empagliflozin as Add-On to Basal Insulin for 78 Weeks Improves Glycemic Control With Weight Loss in Insulin-Treated Type 2 Diabetes (T2DM)

被引：0
|
作者：
Rosenstock, Julio
Jelaska, Ante
Wang, Fei
Kim, Gabriel
Broedl, Uli C.
Woerle, Hans J.
机构：
来源：
DIABETES | 2013年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1102-P
引用
收藏
页码：A285 / A285
页数：1
相关论文
共 50 条
  • [1] Empagliflozin as add-on to basal insulin for 78 weeks improves glycaemic control with weight loss in insulin-treated type 2 diabetes mellitus
    Rosenstock, J.
    Jelaska, A.
    Wang, F.
    Kim, G.
    Broedl, U. C.
    Woerle, H. J.
    [J]. DIABETOLOGIA, 2013, 56 : S372 - S372
  • [2] Empagliflozin as Add-On to Metformin for 24 Weeks Improves Glycemic Control in Patients With Type 2 Diabetes (T2DM)
    Haering, Hans-Ulrich
    Merker, Ludwig
    Seewaldt-Becker, Elke
    Weimer, Marc
    Meinicke, Thomas
    Broedl, Uli C.
    Woerle, Hans J.
    [J]. DIABETES, 2013, 62 : A282 - A282
  • [3] Empagliflozin as Add-On to Pioglitazone With or Without Metformin Improves Glycemic Control in Patients With Type 2 Diabetes (T2DM)
    Kovacs, Christopher
    Seshiah, Veeraswamy
    Swallow, Ros
    Jones, Russell
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2013, 62 : A291 - A291
  • [4] Empagliflozin as Add-On to Metformin Plus Sulfonylurea (SU) for 24 Weeks Improves Glycemic Control in Patients With Type 2 Diabetes (T2DM)
    Haering, Hans-Ulrich
    Merker, Ludwig
    Seewaldt-Becker, Elke
    Weimer, Marc
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2013, 62 : A279 - A279
  • [5] Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM)
    Fonseca, Vivian
    Dejager, Sylvie
    Albrecht, Diego
    Shirt, Lynda
    Schweizer, Anja
    [J]. DIABETES, 2006, 55 : A111 - A111
  • [6] Empagliflozin (EMPA) for ≥76 Weeks As Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans-Juergen
    Broedl, Uli C.
    [J]. ENDOCRINE REVIEWS, 2014, 35 (03)
  • [7] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2014, 63 : A278 - A278
  • [8] Empagliflozin as add-on to basal insulin for 78 weeks improves glycaemic control with weight loss in patients with Type 2 diabetes: a phase III, randomised, double-blind trial (EMPA-REG BASAL™)
    Rosenstock, J.
    Jelaska, A.
    Kim, G.
    Broedl, U. C.
    Woerle, H. J.
    [J]. DIABETIC MEDICINE, 2014, 31 : 64 - 64
  • [9] Empagliflozin Monotherapy for 12 Weeks Improves Glycemic Control in Japanese Patients With Type 2 Diabetes (T2DM)
    Kadowaki, Takashi
    Haneda, Masakazu
    Inagaki, Nobuya
    Taniguchi, Atsushi
    Sakamoto, Masashi
    Koiwai, Kazuki
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2013, 62 : A297 - A298
  • [10] Effect of Meal Replacements On Glycemic Control in Insulin-Treated Patients with T2DM
    Beale, Elizabeth
    Serafin-Dokhan, Sara
    Lee, Wei-An
    Peters, Anne
    [J]. DIABETES, 2010, 59 : A702 - A702
12345